News from biosight, ltd A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 04, 2019, 08:00 ET Biosight Receives Orphan Drug Designation From the FDA for BST-236 for the Treatment of Acute Myeloid Leukemia

Biosight Ltd., a pharmaceutical development company focused on the development of novel oncology therapeutics, announced today that the United States ...


Jul 11, 2018, 08:33 ET BioSight Launches a Phase 2b Clinical Trial of BST-236 as a First-Line Treatment of Acute Myeloid Leukemia

BioSight Ltd., a pharmaceutical development company focused on the development of targeted oncology drugs, announced today that it has received the...


Dec 14, 2017, 07:56 ET BioSight Announces Phase I/II Results of its Cytarabine Pro-Drug BST-236 for Treatment of Acute Leukemia

BioSight Ltd, a pharmaceutical development company, focused on the development of targeted oncology drugs, reports positive final results in a Phase...


Dec 04, 2017, 07:00 ET Final Results of the Phase I/II Clinical Study of BST-236 in Acute Leukemia Patients will be Presented at the 2017 Annual ASH Meeting

BioSight, Ltd, a pharmaceutical development company, focused on the development of targeted oncology therapeutics with reduced toxicity, is pleased...


Aug 09, 2017, 08:00 ET BioSight Completed Patient Enrollment and Treatment in its Extended Acute Leukemia Phase I/II Clinical Trial with BST-236, a Novel Cytarabine Pro-Drug

BioSight, Ltd, a pharmaceutical development company, focused on the development of targeted oncology therapeutics with reduced toxicity, today...


May 16, 2016, 07:00 ET Arkin Holdings and Primera Capital Lead an Investment of $13M in BioSight for an Innovative Treatment of Acute Leukemia

BioSight, Ltd, an Israeli pharmaceutical development company focused on the development of innovative chemotherapy pro-drugs with reduced toxicity,...